Mesoblast (NASDAQ:MESO) Sees Unusually-High Trading Volume – Here’s Why

Mesoblast Limited (NASDAQ:MESO) shares saw strong trading volume on Thursday . Approximately 130,848 shares changed hands during trading, a decline of 43% from the previous session’s volume of 227,658 shares.The stock last traded at $19.0650 and had previously closed at $18.24.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mesoblast in a research report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Mesoblast presently has a consensus rating of “Hold”.

Mesoblast Trading Up 3.8%

The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.41 and a current ratio of 1.58. The business’s 50 day moving average price is $14.68 and its 200-day moving average price is $15.81. The firm has a market cap of $2.45 billion, a price-to-earnings ratio of -67.67 and a beta of 2.08.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of MESO. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Mesoblast by 30.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,383 shares of the company’s stock worth $43,000 after purchasing an additional 558 shares during the period. GAMMA Investing LLC raised its holdings in shares of Mesoblast by 14.1% during the second quarter. GAMMA Investing LLC now owns 7,413 shares of the company’s stock worth $100,000 after purchasing an additional 916 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Mesoblast by 55.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,831 shares of the company’s stock worth $46,000 after buying an additional 1,012 shares during the last quarter. Choreo LLC boosted its holdings in shares of Mesoblast by 15.1% in the 4th quarter. Choreo LLC now owns 12,225 shares of the company’s stock valued at $227,000 after buying an additional 1,600 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Mesoblast in the 4th quarter valued at about $32,000. Institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.